英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

fuzziness    
模糊; 模糊性; 不清晰

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • ADBRY - accessdata. fda. gov
    In ECZTRA 2, 218 ADBRY 300 mg every other week responders (IGA 0 1 or EASI-75) were re-randomized (and dosed) at Week 16 to ADBRY 300 mg every other week (90 subjects), ADBRY 300 mg every 4 weeks (84 subjects) or placebo (44 subjects)
  • ADBRY- tralokinumab-ldrm injection, solution - FDA. report
    In ECZTRA 2, 218 ADBRY 300 mg every other week responders (IGA 0 1 or EASI-75) were re-randomized (and dosed) at Week 16 to ADBRY 300 mg every other week (90 subjects), ADBRY 300 mg every 4 weeks (84 subjects) or placebo (44 subjects)
  • Adbry® for Adults: Efficacy Long-Term Control
    In ECZTRA 3, subjects also used TCS as needed All ECZTRA 1, 2, and 3 trials assessed the primary endpoints of the proportion of subjects with an IGA 0 or 1 at Week 16 and the proportion of subjects with EASI-75 at Week 16
  • Adbry Injection, Solution FDA Label - NDC 50222-350
    In ECZTRA 2, 218 ADBRY 300 mg every other week responders (IGA 0 1 or EASI-75) were re-randomized (and dosed) at Week 16 to ADBRY 300 mg every other week (90 subjects), ADBRY 300 mg every 4 weeks (84 subjects) or placebo (44 subjects)
  • Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two . . .
    In two 52‐week, randomized, double‐blind, placebo‐controlled, phase III trials, ECZTRA 1 and ECZTRA 2, adults with moderate‐to‐severe AD were randomized (3 : 1) to subcutaneous tralokinumab 300 mg every 2 weeks (Q2W) or placebo Primary endpoints were Investigator’s Global Assessment (IGA) score of 0 or 1 at week 16 and ≥ 75% improvement in Eczema Area and Severity Index (EASI 75
  • Table 3, Key Results From ECZTRA 1, 2, 3, and 7 — Initial Treatment . . .
    The analysis was conducted using the repeated measurements model, with baseline IGA, country, prior cyclosporine A use and treatment-by-week interaction as factors, and interaction between week and baseline value as a covariate, based on the hypothetical estimand (primary estimand)
  • label - Food and Drug Administration
    In ECZTRA 2, 218 ADBRY 300 mg every other week responders (IGA 0 1 or EASI-75) were re-randomized (and dosed) at Week 16 to ADBRY 300 mg every other week (90 subjects), ADBRY 300 mg every 4 weeks (84 subjects) or placebo (44 subjects)
  • BLA 761180-S001 ADBRY (tralokinumab) solution for injection, Cycle #2 . . .
    1 1 Product Introduction ADBRY (tralokinumab) is an IgG4 Anti-IL-13-Rα1 α2 monoclonal antibody licensed by the FDA on 12 27 2021 for the indication of treatment (with or without topical
  • BLA 761180 Approval 2021XXXX - Food and Drug Administration
    In ECZTRA 2, 218 ADBRY 300 mg every other week responders (IGA 0 1 or EASI-75) were re-randomized (and dosed) at Week 16 to ADBRY 300 mg every other week (90 subjects), ADBRY 300 mg every 4 weeks (84 subjects) or placebo (44 subjects)
  • Review - Food and Drug Administration
    In ECZTRA 2, 218 ADBRY 300 mg every other week responders (IGA 0 1 or EASI-75) were re-randomized (and dosed) at Week 16 to ADBRY 300 mg every other week (90 subjects), ADBRY 300 mg every 4 weeks (84 subjects) or placebo (44 subjects)





中文字典-英文字典  2005-2009